Erythropoietin Treatment in Peritoneal Dialysis Patients

Nissenson A.R. , Nimer S.D. , Wolcott D.L. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med 1991; 114(5): 402–16.

Eschbach J.W. , Funk D. , Adamson J. , Kuhn I. , Scribner B.H. , Finch C.A. Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 1967; 276: 653–8.

Von Hartitzsch B. , Carr D. , Kjellstrand C.M. , Kerr D.N.S. Normal red cell survival in well dialyzed patients. ASAIO Trans 1973; 19: 471–4.

Chandra M. , Clemons G.K. , McVicar M. Serum erythropoietin levels and hematocrit in end-stage renal disease: influence of the mode of dialysis. Am J Kidney Dis 1988; 12: 208–13.

Eschbach J.W. , Haley N.R. , Egrie J.C. , Adamson J.W. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 1992; 42: 407–16.

Zimmerman S. , Johnson C.A. Peritoneal dialysis and epoietin therapy. New York: Global Medical Communications, 1992.

Lindblad A.S. , Nolph K.D. Hematocrit values in the CAPD/CCPD population: a report of the national CAPD Registry. Perit Dial Int 1990; 10: 275–8.

De Paepe M.B.J. , Schelstraete K.H.G. , Ringoir S.G. , Lameire N.H. Influence of continuous ambulatory peritoneal dialysis on the anemia of end-stage renal disease. Kidney Int 1983; 23: 744–8.

Korbet S.M. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int 1993; 43: 8111–19.

Saltissi D. , Coles G.A. , Napier A.F. , Bentley P. The hematological response to continuous ambulatory peritoneal dialysis. Clin Nephrol 1984; 22: 21–7.

Mehta B.R. , Mogridge C. , Bell J.D. Changes in red cell mass plasma volume and hematocrit in patients on CAPD. TransAm SocArtiflntern Organs 1983; 29: 50–2.

Summerfield G.P. , Bellingham A.J. , Manlove L. Erythropoietin metabolism in patients on hemodialysis and continuous ambulatory peritoneal dialysis. Clin Sci 1982; 62: 479–88.

Lameire N. , Matthys S. , De Paepe M. Red-cell survival in patients on continuous ambulatory peritoneal dialysis. Perit Dial Bull 1986; 6: 65–8.

Wideroe T.E. , Sanengen T. , Halvorsen S. Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis. Kidney Int 1983; 16(Suppl): S208–17.

Hefti J.E. , Blumberg A. , Marti H.R. Red cell survival and red cell enzymes in patients on continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1983; 19: 232–5.

Salahudeen A.K. , Keavey P.M. , Hawkins T. , Wilkinson R. Is anemia during continuous ambulatory peritoneal dialysis really better than during hemodialysis? Lancet 1983; 2: 1046–9.

McGonigle R.J.S. , Husserl F. , Wallin J.D. , Fisher J. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int 1984; 25: 430–6.

Korbet S.M. Comparison of hemodialysis and peritoneal dialysis in the management of anemia related to chronic renal disease. Semin Nephrol 1989; 9(Suppl): 9–15.

Besarab A. , Golper T.A. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. ASAIO Trans 1991; 37: M395–6.

Parthasarathy R. , Johnson C.A. , Zimmerman S.W. Iron dextran use in dialysis patients on erythropoietin (Abstract). J Am Soc Nephrol 1990; 1: 405.

Nissenson A.R. Erythropoietin and peritoneal dialysis: the efficacy of intraperitoneal dosing. Perit Dial Int 1992; 12: 350–2.

MacDougall I.C. , Roberts D.E. , Neubert P. , Dharmasena A.D. , Coles G.A. , Williams J.D. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; 1: 425–7.

Ateshkadi A. , Johnson C.A. , Oxton L.L. , Hammond T.G. , Bohenek W.S. , Zimmerman W. Pharmacokinetics of intraperitoneal, intravenous and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993; 21(6): 635–42.

Bargman J.M. , Breborowicz A. , Rodela H. , Sombolos K. , Oreopoulos D.G. Intraperitoneal administration of recombinant human erythropoietin in uremic animals. Perit Dial Int 1988; 8: 249–52.

Boelaert J.R. , Schurgers M.L. , Matthys E.G. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1989; 9: 95–8.

Lui S.F. , Chung W.W. , Leung C.B. , Chan K. , Lai K.N. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1990; 33: 47–51.

Bargman J.M. , Jones J.E. , Petro J.M. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit Dial Int 1992; 12: 369–72.

Frenken L.A.M. , Struijk D.G. , Coppens P.J.W. , Tiggeler R.G.W.L. , Krediet R.T. , Koene R.A.P. Intraperitoneal administration of recombinant human erythropoietin. Perit Dial Int 1992; 12: 378–83.

Nasu T. , Mitsu H. , Shinohara Y. , Hayashida S. , Ohtuka H. Effect of erythropoietin in continuous ambulatory peritoneal dialysis patients: comparison between intravenous and intraperitoneal administration. Perit Dial Int 1992; 12: 373–7.

Lui S.F. , Law C.B. , Ting S.M. , Li P. , Lai K.N. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1991; 36(5): 246–51.

Eisele G. , Bailie G.R. , Clement C. , Wong E. Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration. Perit Dial Int 1992; 12: 34–6.

MacDougall I.C. , Davies M.E. , Hut ton R.D. The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5: 950–5.

Reddingius R.E. , Schroder C.H. , Monnens L.A.H. Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis. Eur J Pediatr 1992; 151: 540–2.

Hirasawa Y. , Hirashima Y. , Arakawa M. Clinical evaluation of recombinant human erythropoietin (EPO) on renal anemia. Kidney Dial 1990; 1: 121–34.

Nissenson A.H. , Swartz R. , Zimmerman S. , Watson A. , and the Epogen Study Group. A double-blind, placebocontrolled study of recombinant human erythropoietin in peritoneal dialysis patients (Abstract). J Am Soc Nephrol 1990; 1: 405.

Bunke M. , Bartlett D.K. , Brier M.E. , Golper T.A. Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in continuous ambulatory peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1993; 9: 331–5.

Raja R. , Bloom E. , Johnson R. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in continuous ambulatory peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1993; 9: 177–80.

Struijk D.G. , Koomen G.C. , Krediet R.T. , Ariaz L. Accuracy of erythropoietin determination in dialysate of CAPD patients. Perit Dial Int 1990; 10: 184–5.

Mactier R.A. , Khanna R. , Twardowski Z. Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in CAPD. J Clin Invest 1987; 80: 1311–16.

Flessner M.F. , Dedrick R.L. , Schultz J.S. Exchange of macromolecules between peritoneal cavity and plasma. Am J Physiol 1985; 248: H15–25.

Struijk D.G. , Koomen G.C.M. , Krediet R.T. , Ariaz L. Indirect measurement of lymphatic absorption with inulin in continuous ambulatory peritoneal dialysis. Perit Dial Int 1990; 10: 141–5.

Frenken L.A.M. , van Lier H.J.J. , Jordans J.G.M. Identification of the component part in an epoetin alpha preparation that causes pain after subcutaneous injection. Am J Kidney Dis 1993; 22(4): 553–6.

McMorrow R.G. , Davis D.S. The effect of an increased hematocrit on solute removal in peritoneal dialysis (Abstract). Perit Dial Int 1991; 11(Suppl 1): 177.

Burkart J.M. , Freedman B.I. , Rocco M.V. Effect of hematocrit on peritoneal clearance in CAPD patients (Abstract). Perit Dial Int 1992; 12(Suppl 1): 103.

Miranda B. , Selgas R. , Rinon C. Treatment of the anemia with human recombinant erythropoietin in CAPD patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in continuous ambulatory peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1990; 6: 296–301.

Bajo M.A. , Selgas R. , Miranda B. Medium-term response to H- R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in continuous ambulatory peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1991; 7: 296–300.

Hutchinson A.J. , Ofsthun N.J. , Howarth D. , Gokal R. The effect of hemoglobin concentration on peritoneal mass transfer and drain volume in continuous ambulatory peritoneal dialysis. Perit Dial Int 1992; 12: 230–3.

Taylor J.E. , MacTier R.A. , Henderson I.S. , Belch J.J.F. , Steward W.K. Dialysis efficiency in continuous ambulatory peritoneal dialysis patients treated with erythropoietin. Perit Dial Int 1992; 12: 221–6.

Schollmeyer P. , Lubrich-Birkner I. , Steinhauer H.B. Effect of recombinant human erythropoietin on anemia and dialysis: efficiency in patients undergoing CAPD. Contrib Nephrol 1990; 87: 95–104.

Steinhauer H.B. , Lubrich-Birkner I. , Dreyling K.W. , Schollmeyer P. Effect of human recombinant erythropoietin on anaemia and dialysis efficiency in patients undergoing continuous ambulatory peritoneal dialysis. Eur J Clin Invest 1991; 21: 47–52.

Steinhauer H.B. , Lubrich-Birkner I. , Schollmeyer P. Effect of human recombinant erythropoietin on dialysis efficiency in CAPD. Contrib Nephrol 1991; 89: 214–23.

Vega N. , Fernandez A. , Hortal L. Peritoneal dialysis efficiency in CAPD patients in treatment with rHuEPO (Abstract). Perit Dial Int 1992; 12(Suppl 1): 168.

Korbet S.M. , Vonesh E.F. , Firanek C.A. The effect of hematocrit on peritoneal transport. Am J Kidney Dis 1991; 18: 573–8.

Richmond D. , Reft C. , Poseno M. , Shea S. , Broyan P. What will EPO do to ultrafiltration (Abstract)? Perit Dial Int 1991; 11(Suppl 1): 226.

Habwe V. , Lew S. , Watson J. , Early S. , Bosch J.P. Effects of haematocrit on solute removal in CAPD (Abstract). Kidney Int 1989; 35: 271.

Eschbach J.W. , Abdulhadi M.H. , Browne J.K. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992–1000.

Nissenson A.R. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. SeminNephrol 1989; 9(Suppl 2): 25–31.

Wolcott D.L. , Marsh J.T. , La Rue A. , Carr C. , Nissenson A.R. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; 14: 478–85.

Delano B.G. Improvement in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14(Suppl 1): 14–18.

Marsh J.T. , Brown W.S. , Wolcott D.L. , Nissenson A.R. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39: 155–63.

Auer J. , Simon G. , Stevens J. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 1992; 12: 40–2.

Nissenson A.R. , for the National Cooperative rHu Erythropoietin Study Group. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Am J Kidney Dis 1991; 4(Suppl 1): 24–33.

Golper T.A. The effect of recombinant erythropoietin on the early hematocrit rise after CAPD initiation. Perit Dial Int 1992; 12: 37–9.

Granolleras C. , Branger B. , Beau M.C. , Deshodt G. , Alsabadani B. , Shaldon S. Experience with daily self administered subcutaneous erythropoietin. In: Baldamus C.A. , Scigalla P. , Wieczorek L. , Koch K.M. , eds. Erythropoietin: from molecular structure to clinical application. Contrib Nephrol, Basel: Karger, 1989; 76: 143–8.

Kusunoki M. , Kimura K. , Nakamura M. , Isaka Y. , Yoneda S. , Abe H. Effects of hematocrit variations on cerebral blood flow and oxygen transport in ischemic cerebrovascular disease. J Cereb Blood Flow Met 1981; 1: 413–17.

Jan K. , Chien S. Effect of hematocrit variations on coronary hemodynamics and oxygen utilization. Am J Physiol 1977; 233(1): H106–13.

Crowell J.W. , Ford R.G. , Lewis V.M. Oxygen transport in hemorrhagic shock as a function of the hematocrit ratio. Am J Physiol 1959; 196(5): 1033–8.